Kamada Ltd. (KMDA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kamada Ltd. (KMDA) Healthcare & Pipeline Overview

Kamada Ltd., based in Israel, develops and markets plasma-derived protein therapeutics, focusing on specialty and generic drugs. With a diverse portfolio including treatments for rabies, cytomegalovirus, and alpha-1 antitrypsin deficiency, Kamada leverages strategic partnerships to distribute its products globally, maintaining a presence in the specialty pharmaceutical sector.

What Is the Investment Thesis for KMDA?

With a market capitalization of $461M and a P/E ratio of 20.86, the company demonstrates profitability, supported by a healthy profit margin of 11.2% and a gross margin of 42.3%. A key value driver is Kamada's diverse portfolio of plasma-derived protein therapeutics, addressing niche markets with limited competition. Growth catalysts include the expansion of its distribution network and the potential for new product approvals. The company's strategic partnerships with Takeda, PARI GmbH, and Kedrion Biopharma enhance its market reach and product development capabilities. However, potential risks include regulatory hurdles, competition from biosimilars, and dependence on plasma supply.

Based on FMP financials and quantitative analysis

KMDA Key Highlights

Market Cap of $461M reflecting its position as a key player in the specialty pharmaceutical market.

• P/E ratio of 20.86 indicating investor confidence in its earnings potential compared to the industry average.
• Profit Margin of 11.2% demonstrating efficient cost management and profitability in a competitive landscape.
• Gross Margin of 42.3% highlighting the value-added nature of its plasma-derived protein therapeutics.
• Dividend Yield of 2.92% offering investors a steady income stream while the company pursues growth opportunities.

Who Are KMDA's Competitors?

KMDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are KMDA's Key Strengths?

Specialized expertise in plasma-derived protein therapeutics.

• Diverse product portfolio targeting niche markets.
• Strategic partnerships with established pharmaceutical companies.
• Global distribution network.

What Are KMDA's Weaknesses?

Dependence on plasma supply.

• Limited scale compared to larger pharmaceutical companies.
• Vulnerability to regulatory changes.
• Geographic concentration in certain markets.

What Could Drive KMDA Stock Higher?

Potential FDA approval for new indication of existing product (Q4 2026).

• Expansion of distribution network in Asia-Pacific region.
• Progress in clinical trials for novel plasma-derived therapy (Phase 2 results expected H1 2027).

What Are the Key Risks for KMDA?

Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.

• Regulatory delays in key markets.
• Competition from biosimilars.
• Fluctuations in plasma supply and pricing.
• Dependence on strategic partnerships for distribution.

What Are the Growth Opportunities for KMDA?

• Expansion of GLASSIA Market: GLASSIA, Kamada's intravenous AATD treatment, presents a significant growth opportunity. The global AATD market is projected to reach $2.5 billion by 2028, driven by increased diagnosis rates and awareness. Kamada can capitalize on this trend by expanding its marketing efforts and distribution network, particularly in underserved regions. A key competitive advantage is GLASSIA's established safety profile and efficacy, which can drive adoption among healthcare providers.
• Strategic Partnerships for New Product Development: Kamada's strategic partnerships with Takeda, PARI GmbH, and Kedrion Biopharma offer opportunities for collaborative product development and market expansion. By leveraging these partnerships, Kamada can access new technologies, expand its product portfolio, and enter new geographic markets. For example, collaborations focused on developing novel plasma-derived therapies could unlock significant growth potential in the orphan drug market.
• Geographic Expansion in Emerging Markets: Emerging markets, such as Asia-Pacific and Latin America, represent a significant growth opportunity for Kamada. These regions are experiencing increasing demand for specialized therapies and offer favorable regulatory environments for pharmaceutical companies. By establishing distribution partnerships and tailoring its product offerings to local needs, Kamada can tap into these high-growth markets and diversify its revenue streams. This expansion could contribute significantly to revenue growth over the next 3-5 years.
• Development of Novel Plasma-Derived Therapies: Kamada's expertise in plasma fractionation and protein purification positions it well to develop novel plasma-derived therapies for unmet medical needs. By investing in research and development, Kamada can create innovative products that address specific patient populations and command premium pricing. This strategy aligns with the growing trend towards personalized medicine and offers the potential for significant long-term growth. Focus areas could include rare diseases and autoimmune disorders.
• Increased Adoption of KamRho (D) Products: Kamada's KamRho (D) IM and IV products, used for the prevention of hemolytic disease of newborns and treatment of immune thrombocytopenic purpura, respectively, offer a steady growth opportunity. With increasing awareness of Rh incompatibility and advancements in prenatal care, the demand for these products is expected to rise. Kamada can further penetrate the market by expanding its educational outreach to healthcare providers and promoting the benefits of its KamRho (D) products.

What Threats Does KMDA Face?

• Competition from biosimilars.
• Pricing pressures from healthcare providers.
• Disruptions in plasma supply.
• Adverse regulatory changes.

What Are KMDA's Competitive Advantages?

• Specialized expertise in plasma fractionation and protein purification.
• Established relationships with plasma suppliers.
• Strategic partnerships with leading pharmaceutical companies.
• Proprietary product portfolio with limited competition.
• Global distribution network.

What Does KMDA Do?

Kamada Ltd., founded in 1990 and headquartered in Rehovot, Israel, is a biopharmaceutical company specializing in the development, production, and marketing of plasma-derived protein therapeutics. The company operates through two primary segments: Proprietary Products and Distribution. Its proprietary product portfolio includes a range of treatments for various conditions, such as KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for cytomegalovirus prophylaxis in transplant patients, WINRHO SDF for immune thrombocytopenic purpura and rhesus isoimmunization suppression, HEPAGAM B for hepatitis B prevention, VARIZIG for varicella prophylaxis, and GLASSIA for intravenous Alpha-1 Antitrypsin Deficiency (AATD). In addition to its proprietary products, Kamada distributes a variety of pharmaceutical products through strategic partnerships. These include BRAMITOB for chronic pulmonary infection management, FOSTER for asthma treatment, and PROCYSBI for nephropathic cystinosis. Kamada markets its products through strategic partnerships with companies like Takeda Pharmaceuticals, PARI GmbH, and Kedrion Biopharma, as well as through a network of distributors in international markets. This diversified approach allows Kamada to maintain a global presence and address a wide range of therapeutic needs.

What Products and Services Does KMDA Offer?

• Develop and market plasma-derived protein therapeutics.
• Offer treatments for rabies, cytomegalovirus, and alpha-1 antitrypsin deficiency.
• Distribute pharmaceutical products through strategic partnerships.
• Provide therapies for immune thrombocytopenic purpura and rhesus isoimmunization suppression.
• Offer products for the prevention of hepatitis B and varicella.
• Develop and market snake bite antiserum.
• Distribute products for the management of chronic pulmonary infection and asthma.
• Provide treatments for nephropathic cystinosis and alpha-mannosidosis.

How Does KMDA Make Money?

• Develop and manufacture proprietary plasma-derived protein therapeutics.
• Distribute pharmaceutical products from strategic partners.
• Generate revenue through product sales and distribution agreements.
• Focus on niche markets with limited competition.

What Industry Does KMDA Operate In?

Kamada Ltd. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and stringent regulatory requirements. The global market for plasma-derived products is experiencing steady growth, driven by increasing demand for specialized therapies and advancements in plasma fractionation technologies. Kamada differentiates itself through its focus on niche markets and strategic partnerships. Competitors include larger pharmaceutical companies with broader product portfolios, but Kamada's specialization and established distribution networks provide a competitive edge. The industry is also influenced by factors such as regulatory changes, pricing pressures, and the availability of plasma supply.

Who Are KMDA's Key Customers?

• Hospitals and healthcare providers.
• Transplant centers.
• Pharmacies and distributors.
• Patients with specific medical conditions (e.g., rabies, cytomegalovirus, AATD).

Kamada Ltd. Financial Trajectory

Kamada Ltd. (KMDA) reported $54.9M in revenue for Q2 FY2026, reflecting 21.4% growth compared to the prior quarter. The company recorded net income of $9.3M, with diluted EPS of $0.16. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, KMDA averaged $0.09 in diluted EPS.

Company Profile

Kamada Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Rehovot, IL. The company is led by CEO Amir London. KMDA has traded publicly since 2013.

How Kamada Ltd. Is Valued

Kamada Ltd. carries a market capitalization of $461M, placing it in the small-cap category. Analyst price targets span from $11.00 to $15.00, with a consensus of $13.00. At the current price of $7.99, that implies approximately 63% upside potential. Relative to its peer group, KMDA's quantitative score of 81/100 is above the peer average of 56/100.

Return on equity for Kamada Ltd. stands at 8.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.8%, showing how much profit it generates from its asset base. KMDA trades at a trailing price-to-earnings ratio of 20.86, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.6%, the inverse of the P/E and a quick read on earnings relative to price.

Kamada Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.64 places it in the safe zone, indicating low near-term bankruptcy risk.

Kamada Ltd. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 5.2% above estimates on average.

Over the past six months, Kamada Ltd. insiders filed 85 SEC Form 4 transactions — 40 sales and 45 purchases. On net that is roughly 257K shares acquired (about $1.8M) — insiders putting money in tends to read as conviction.

KMDA Financials

KMDA Latest News

KMDA Analyst Consensus

KMDA MoonshotScore

Kamada Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources